Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics, Structural Bioinformatics, J&J, Applied Biosystems

Premium

Hybrigenics Raises Additional $14.8M

 

Hybrigenics said last week that it has raised 16.8 million, or roughly $14.8 million, in a Series C round of venture capital financing.

The financing, which brings Hybrigenics’ total take to 47 million since its founding in December 1997, will be used to bolster its therapeutic-target validation, emphasizing infectious-diseases drug discovery. The funds will also help support Hybrigenics’ internal and external growth, and to reinforce its international business presence, the company said.

Life Sciences Partners, based in the Netherlands and Germany, led the round.

 

J&J Expands Protein Structure Determination Contract With SBI

 

Structural Bioinformatics said last week that it has expanded the scale of its protein crystallization work for Johnson & Johnson Pharmaceutical Research and Development. San Diego-based SBI first began determining the structures of crystallized proteins and drug-protein complexes for J&J in January 2001. David Muth, SBI’s president, declined to disclose the number of new proteins SBI would study for J&J, but said the new collaboration would expand the number of targets and extend the timeframe of the contract research. SBI has access to MAR Research x-ray crystallography equipment at the University of California, San Diego, x-ray crystallography facility.

 

ABI Expects to Sell 50 TOF/TOFs in 2002; Sales Could be Worth $38M

 

Applied Biosystems expects to sell around 50 of its 4700 Proteomics Analyzer MALDI TOF/TOF machines during 2002, according to Banc of America analyst James Reddoch. The potential sales would represent around 4 percent of ABI’s total, or $38 million. In a report, Reddoch said ABI may post strong sales of MALDI-TOF/TOFs even “in a tough environment,” but that “we would be cautious buying ABI [stock] before the company reports its [revenues for the third quarter of fiscal 2002].”

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.